Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

Novo Nordisk's new GLP1 Receptor Agonist Amycretin recently completed phase 2 trials and delivered fantastic results:

The results are pretty amazing:
When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks). People treated with placebo experienced an estimated 1.9%, 2.3% and 2.0% body weight gain, respectively.
On a dose of 5mg after 28 weeks (just 6 months), 16% body weight loss is nothing short of amazing.
Amycretin isn't the only new GLP1 on the market though – let's dive in and see how it compares to other formulations under development.
What is Amycretin?
We've covered Amycretin before:

Amycretin is a dual agonist (similar to but different from Tirzepatide, which is a dual agonist) being developed by Novo Nordisk. It influences the following hormones in your body:
- Amylin
- GLP1
The side effects seem to be largely unchanged from Semaglutide and Tirzepatide, with no new drastic negative side effects being introduced so far.
While the results from the trial have not been released yet in full, it serves as another chance to
How does Amycretin compare to other new drugs?
There are a few new GLP1s on the horizon:
- Retatrutide (Eli Lilly)
- MariTide/AMG-133 (Amgen)
- Danuglipron (Pfizer)
Amycretin vs. Retatrutide
Retatrutide is a triple agonist – but more agonists does not always mean better performance. A relatively high dosage of 12mg of Retatrutide "only" produced 17% body weight loss at 24 weeks.

Amycretin vs. MariTide
MariTide produced 20% of weight loss after 52 weeks. While 20% body weight loss after just one year is impressive, the fact that they only made available a 52 week stat likely means the drug did not do impressively on a shorter timescale.

Amycretin vs Danuglipron
Danuglipron delivered less than stellar results the last time it was tested:
Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks
The study was also relatively small, but the variability in outcomes and the lack of loss near 26 weeks compared to Amycretin makes Amycretin the clear choice.
Pfizer is in the game, but it's likely going to take a bit more ingenuity/engineering to reach the current phase 2 results produced by Amycretin.
Clearly the average consumer is spoiled for choice when it comes to new GLP1s under development, but Amycretin is indeed a powerful competitor.
What are the adverse side effects?
One thing we don't have enough information on are the changes in occurrence or frequency of adverse side effects.
Unfortunately the entirety of the research is not yet published publicly, so we can't know this, but given that prior trials of Amycretin did not surface completely new negative side effects, and the press release did not mention any, there may only be issues of increased severity (if any) of existing side effects.
We're looking forward to the full release of the trial data.